FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/04/083850 [Registered on: 02/04/2025] Trial Registered Prospectively
Last Modified On: 01/04/2025
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Other 
Public Title of Study   A study of past events to evaluate the occurrence of cardiovascular disease in patients with Type 2 diabetes in India 
Scientific Title of Study   A Cross-Sectional Study to Assess the Prevalence of Cardiovascular Disease (CVD) in Individuals with Type 2 Diabetes Mellitus (T2DM) in India 
Trial Acronym  CAPTIVATE India 
Secondary IDs if Any  
Secondary ID  Identifier 
DAS-8323 Version 1.0 Dated 24 December 2024  Protocol Number 
U1111-1310-3556  UTN 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Arjun Nair 
Designation  Senior Medical Advisor 
Affiliation  Novo Nordisk India Private Limited  
Address  NXT-2, 1 & 2nd Floor,
Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli,
Bangalore
KARNATAKA
560045
India 
Phone  9895067672  
Fax    
Email  iajn@novonordisk.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Maya Sharma 
Designation  Vice President - Clinical, Medical, Regulatory & Pharmacovigilance 
Affiliation  Novo Nordisk India Private Limited, 
Address  Nxt Tower - 2, Floor 1 & 2 Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli,

Bangalore
KARNATAKA
560045
India 
Phone  09911497869  
Fax    
Email  YRMS@novonordisk.com  
 
Details of Contact Person
Public Query
 
Name  Dr Maya Sharma 
Designation  Vice President - Clinical, Medical, Regulatory & Pharmacovigilance 
Affiliation  Novo Nordisk India Private Limited, 
Address  Nxt Tower - 2, Floor 1 & 2 Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli,

Bangalore
KARNATAKA
560045
India 
Phone  09911497869  
Fax    
Email  YRMS@novonordisk.com  
 
Source of Monetary or Material Support  
Novo Nordisk India Private Limited NXT-2, 1 & 2nd Floor, Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli, Bangalore - 560045  
 
Primary Sponsor  
Name  Novo Nordisk India Private Limited  
Address  NXT-2, 1 & 2nd Floor, Embassy Manyata Business Park, Nagavara Village, Kasaba Hobli, Bangalore - 560045  
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 18  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr KM Prasanna Kumar  CDEC Clinic,   No. 410/A, 1st Stage, 3rd Block, HBR Layout, Bengaluru, Karnataka 560043
Bangalore
KARNATAKA 
9845156811

kmpk@gmail.com 
Dr Hitesh Punyani  Chaitanya cardio diabetes centre  33/1, Ramesh Nagar,New Delhi 110026
New Delhi
DELHI 
9810836090

hiteshpunyani@gmail.com 
Dr A G Unnikrishnan  Chellaram Hospital - Diabetes Care & Multispeciality  Chellaram Hospital, Patil Nagar, Bavdhan, Pune, Maharashtra 411021
Pune
MAHARASHTRA 
8605011934

uag@cdi.org.in 
Dr Krishna Seshadri   Chennai Diabetes & Endocrinology Clinic,   Plot No.175, Door No.20, Brahmaputra St, Palaniappa Nagar, Valasaravakkam, Chennai, Tamil Nadu 600087
Chennai
TAMIL NADU 
9940068170

drkrishnaendocrine@gmail.com 
Dr Jayashree Gopal  DiabEndoIndia  26 Bishop Garden, Off Greenways Road, Chennai 600028
Chennai
TAMIL NADU 
9841024613

jayashreegopaldr@gmail.com 
Dr Rajat Gupta  Dr. Guptas Diabetes & Thyroid, Skin and Laser Centre  1446, Sector 15, Panchkula, Haryana, 134113
Panchkula
HARYANA 
9256076287

raguptaendo@gmail.com 
Dr V Mohan  Dr. Mohan’s Diabetes Specialities Centre / Madras Diabetes Research Foundation  No: 04 Conran Smith Road, Gopalapuram, Chennai – 600086, Tamil Nadu.
Chennai
TAMIL NADU 
044-43968888

drmohans@diabetes.ind.in 
Dr Vijay Negalur  Dr. Negalurs Diabetes and Thyroid centre  Ovala, GB road, Thane, Maharashtra- 400615
Thane
MAHARASHTRA 
9821321772

negalur@msn.com 
Dr Rajiv Kovil  Dr. Rajiv Kovil Diabetes care centre,   Zandra Healthcare Pvt. Ltd., Janakpuri, 1st Floor, Lallubhai Park, Andheri, Mumbai
Mumbai
MAHARASHTRA 
9820127777

rajivrkovil@gmail.com 
Dr Vaibhav Jain  Fortis Memorial Research Institute (FMRI),   SECTOR-44, GURGAON, Gurgaon, Haryana - 122002
Gurgaon
HARYANA 
9758799303

vaibhavjain1000@yahoo.co.in 
Dr Shehla Shaikh  KGN Diabetes and Endocrine Centre  Shop No 10, 1st Floor, Patel Arcade, Nagpada-Mumbai Central, Mumbai - 400008
Mumbai
MAHARASHTRA 
98209 84842

drshehlas@gmail.com 
Dr RK Jain  KIMS Hospital,   1-8-31/1, Minister Road, Secunderabad - 500003
Hyderabad
TELANGANA 
9848029443

Kumarpre@hotmail.com 
Dr Manoj Chawla  Leena Diabcentre  DN Nagar, Leena Diabcentre 702, Cosmos Plaza JP Road Andheri-W DN Nagar, Mumbai Maharashtra
Mumbai
MAHARASHTRA 
9820002333

drmanojchawla@yahoo.com 
Dr Arun Pandey  Lucknow Endocrine Diabetes and thyroid Clinic (LEDTC),   5/425 Viraj Khand, Gomti nagar, behind Divine Hospital, Lucknow, Uttar Pradesh- 226010
Lucknow
UTTAR PRADESH 
7081057777

drarunendocrine@gmail.com 
Dr R Santosh  Magna Centres for Obesity & Endocrinology  D-4, Rd Number 9, Durga Bhawani Nagar, MLA Colony, Film Nagar, Hyderabad, Telangana 500033
Hyderabad
TELANGANA 
9959205556

dr.rsantosh@gmail.com 
Dr P Harikrishnan Parthasarthy  Shri Krishnasai Clinic  No.6 Rathinapuri, 3rd street, Koyambedu, Chennai, Tamil Nadu
Chennai
TAMIL NADU 
9790735862

krishnankala@hotmail.com 
Dr Tom Babu  Silverline Hospital  K P Vallon Road, Kadavanthra PO, Kochi, kerala- 682020
Ernakulam
KERALA 
9995578888

tomluciya@gmail.com 
Dr Yash Patel  Swasthya Diabetes Care  Opposite Jaimangal,BRTS bus stop, 132 ft ring road, Naranpura, Ahmdabad 380013, Gujarat
Ahmadabad
GUJARAT 
9586836069

yash@swasthyaindia.com 
 
Details of Ethics Committee  
No of Ethics Committees= 18  
Name of Committee  Approval Status 
Alchemist Hospital Ethics Committee  Submittted/Under Review 
Chellaram Diabetes lnstitute - institutional Ethics Gommittee   Submittted/Under Review 
Conscience Independent Ethics Committee (CIEC)  Approved 
Gene Bandhu  Submittted/Under Review 
Giridhar Eye hospital,Ethics Committee  Submittted/Under Review 
Institutional Ethics Committee, Fortis Memorial Research Institute (FMRI)  Approved 
KIMS Ethics Committee  Submittted/Under Review 
Madras Diabetes Research Foundation Institutional Ethics Committee  Approved 
Pranav Diabetes Centre Ethics Committee  Submittted/Under Review 
Ripon Independent Ethics Committee Unit of Quinary Clinical Research  Submittted/Under Review 
Ripon Independent Ethics Committee Unit of Quinary Clinical Research  Submittted/Under Review 
Ripon Independent Ethics Committee, Unit of Quinary Clinical Research  Submittted/Under Review 
S2J Independent Ethics Committee  Submittted/Under Review 
Sanjivani Lung Center Ethics Committeee  Submittted/Under Review 
ZanEthics, Institutional Ethics committee of Zandra Healthcare Pvt. Ltd  Submittted/Under Review 
ZanEthics, Institutional Ethics committee of Zandra Healthcare Pvt. Ltd  Submittted/Under Review 
ZanEthics, Institutional Ethics committee of Zandra Healthcare Pvt. Ltd  Submittted/Under Review 
ZanEthics, Institutional Ethics committee of Zandra Healthcare Pvt. Ltd  Submittted/Under Review 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: E135||Other specified diabetes mellituswith circulatory complications,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NA  NA 
Comparator Agent  NA  NA 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  The following criteria are necessary for subjects to be eligible for this study:
1.Male of female individuals with T2DM, greater than or equal to 18 years of age
2. A confirmed diagnosis of T2DM, and the availability of data before ethical clearance at every participating institution
3. Medical records available between 01 January 2024 to 30 September 2024 ought to have the
data points required for the primary and secondary objectives. Medical records must have at
least 6 months (greater than or equal to 180 days) of follow-up data from the date of diagnosis
 
 
ExclusionCriteria 
Details  Subjects who meet any of the following criteria will be disqualified from entering the study:
1.Diagnosis of Type 1 diabetes, or maturity-onset diabetes of the young (MODY)
2.Known congenital heart disease or malformation
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Proportion of individuals with established CVD i.e. who have been diagnosed with either cerebrovascular disease, coronary heart disease (CHD), heart failure, cardiac arrhythmia or conduction abnormalities, aortic disease, peripheral artery disease (PAD), or carotid artery disease  At least 180 days (6 months) from the date of diagnosis 
 
Secondary Outcome  
Outcome  TimePoints 
· Proportion of individuals with renal disease & cardio-renal risk factors.
· Characterize individuals based on demographics, clinical parameters & treatment patterns
 
At least 180 days (6 months) from the date of diagnosis 
 
Target Sample Size   Total Sample Size="6500"
Sample Size from India="6500" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   14/04/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="7"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   This is a multi-center, non-interventional, cross-sectional study assessing the prevalence of CVD and describing cardio-renal risk factors among individuals with T2DM in India. By estimating the prevalence of CVD and exploring associated cardio-renal risk factors, the study seeks to provide valuable insights that will help contextualize the disease burden and unmet needs. Additionally, the study strives to provide the most recent evidence on CVD prevalence in Indian individuals with T2DM, focusing on baseline demographic and clinical characterization. 
Close